Who
Kristen Ambrose
SVP & Chief Accounting Officer
Company insider
Files Form 4 as: SVP & Chief Accounting Officer, Vertex Pharmaceuticals.
In numbers
- Trades disclosed
- 58
- Buys
- 0
- Sells
- 14
- Bought
- $0
- Sold
- $6.9M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Feb 2022
- Last trade
- 28 Aug 2026
- Last filed
- 1 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Aug 2026filed 1 Sep 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 28 Aug 2026filed 1 Sep 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $173K357 at $483.36 | filing |
| 26 Feb 2026filed 2 Mar 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $173K357 at $483.36 | filing |
| 25 Feb 2026filed 26 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $108K223 at $486.35 | filing |
| 25 Feb 2026filed 26 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $108K223 at $486.35 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $265K546 at $485.11 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $265K546 at $485.11 | filing |
| 18 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $302K638 at $473.68 | filing |
| 18 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $302K638 at $473.68 | filing |
| 17 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,809 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $289K598 at $483.75 | filing |
| 17 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $762K1,557 at $489.46 | filing |
| 17 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,809 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $289K598 at $483.75 | filing |
| 17 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $762K1,557 at $489.46 | filing |
| 13 Feb 2026filed 18 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $679K1,393 at $487.76 | filing |
| 13 Feb 2026filed 18 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $679K1,393 at $487.76 | filing |
| 11 Feb 2026filed 12 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $634K1,376 at $460.43 | filing |
| 11 Feb 2026filed 12 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $634K1,376 at $460.43 | filing |
News
Head to Head Analysis: Caribou Biosciences (NASDAQ:CRBU) & Vertex Pharmaceuticals (NASDAQ:VRTX)VRTX · tickerreport.com · 14 Oct 2026Vertex Pharmaceuticals Incorporated: Vertex to Present New Data on ALYFTREK at the North American Cystic Fibrosis ConferenceVRTX · finanznachrichten.de · 9 Oct 2026
0 headlines in the last 90 days name Kristen Ambrose; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.